Influence of Electronic Patient Reported Outcomes (ePROMs) in Surgical Therapy for Prostate Cancer on Postoperative Outcome

Prostate Cancer Clinical Trial

— PRO-P  

Official title:

Influence of Electronic Patient Reported Outcomes (ePROMs) in Surgical Therapy for Prostate Cancer on Postoperative Outcome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05644821
• Other study ID #: 2022-2148
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2023
• Est. completion date: March 2025

Study information

• Verified date: January 2024
• Source: Heinrich-Heine University, Duesseldorf
• Contact: Dominik Fugmann, MD
• Phone: +49 (0)211-81 18 33 8
• Email: dominik.fugmann[@]med.uni-duesseldorf.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study investigates the influence of structured follow-up using ePROMS in the 1st year after prostatectomy on the postoperative course. It will be examined whether this intervention leads to early detection of postoperative symptoms and whether the subsequent initiation of further measures lead to an improvement of incontinence, symptom burden, quality of life and patient competence.

Description:

PRO-P is planned as a multicenter, prospective, and two-arm randomized control group study in which ePROMs will be performed in a standardized fashion once before and six times (intervention group) or three times (control group) after primary prostatectomy in patients with PCa. PROMs are collected either web-based or through a dedicated app and entered by the patient using either a mobile device or computer. Patients are invited to enter ePROMS into the app or web tool through email and app-driven push messages. Patients who are incontinent (at least one pad in 24 hours) at the 6-week postoperative survey are randomized into two groups: The intervention group and the control group. In the intervention group, when the respective questionnaire cut-off values are exceeded in the ePROM survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center as well as subsequent measures, if necessary. This is done at 6 weeks postoperatively and at 12, 18, 24, 36 and 52 weeks postoperatively. In the control group, ePROMs are recorded 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group thus receives treatment in accordance with the current clinical routine. The mechanisms of action of the intervention will be investigated within the framework of a qualitative process evaluation. Characteristics on the patient level (e.g., treatment-related attitudes, comorbidity, social support), on the practitioner level (e.g., communication skills), on the organizational level, and the interactions between the levels (e.g., patient-doctor relationship) will be explored. The goal is to develop an intervention model, or to describe the effective elements of the intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 336
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age = 18 y
• legal capacity
• sufficient knowledge of the German language
• prostate carcinoma, TNM T1-4 NX N0-1 M0-1c
• primary radical prostatectomy planned
• mobile input device or PC available
• ability to either receive emails or install a special app on cell phone and receive push messages, with guidance or assistance if necessary
• ability to complete electronic questionnaires, with guidance or assistance if necessary

Exclusion Criteria:

• palliative treatment situation (life expectancy < 1 year)
• preoperative urinary incontinence (at least one pad per 24 hours)

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• complex intervention
The intervention has several elements: Regular symptom monitoring via ePROMs Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study, 4) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist.
• current clinical practice
current clinical practice

Locations

Country	Name	City	State
Germany	University Clinic Bonn, Urology	Bonn	North Rhine Westpahlia
Germany	Klinikum Dortmund gGmbH, Urology	Dortmund	North Rhine Westphalia
Germany	University Clinic Düsseldorf, Urology	Düsseldorf	North Rhine Westphalia
Germany	University Clinik Bochum, Marienhospital Herne, Urology	Herne	North Rhine Westphalia
Germany	University Clinic Münster, Urology	Münster	North Rhine Westphalia

Sponsors (10)

Lead Sponsor	Collaborator
Heinrich-Heine University, Duesseldorf	Deutsche Krebsgesellschaft e.V., Klinikum Dortmund gGbmH, Marienhospital Herne, Techniker Krankenkasse, University Hospital Muenster, University Hospital of Cologne, University Hospital, Bonn, University Hospital, Essen, University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	urinary incontinence	The Expanded Prostate Cancer Index Short Form (EPIC-26) is a questionnaire that assesses symptoms and functions of people with prostate cancer in 5 domains. A total of 100 points can be achieved for each domain, with a higher score indicating better function. The urinary incontinence domain consists of four items. To calculate the primary endpoint, the difference between the scores on the urinary incontinence scale of the EPIC-26 is taken at 52 and 6 weeks. Changes regarding urinary incontinence (Minimally Important Difference (MID) >= 9) at 52 weeks postoperatively compared with 6 weeks postoperatively are considered.	52 weeks
Secondary	EPIC-26: changes in sexual function	Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes in in sexual function according to EPIC-26 (MID >= 10).	52 weeks
Secondary	EPIC-26: changes in irritative/obstructive symptoms	Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes in irritative/obstructive an gastrointestinal symptoms according to EPIC-26 (MID >= 7).	52 weeks
Secondary	EPIC-26: changes in gastrointestinal symptoms	Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes an gastrointestinal symptoms according to EPIC-26 (MID >= 5).	36 months
Secondary	EPIC-26: changes in vitality/hormonal function	Similar to the primary endpoint, changes at 52 weeks postoperatively compared with 6 weeks postoperatively are considered for the changes in vitality/ hormonal function according to EPIC-26 (MID >= 4).	52 weeks
Secondary	EQ-5D-5L: changes in health-related quality of life (HRQoL)	The European Quality of Life Five-Dimensions Questionnaire (EQ-5D-5L) measures health-related quality of life on five scales: 1. mobility, 2. ability to care for oneself, 3. activities of daily living, 4. pain/physical discomfort, and 5. anxiety/dejection, each of which is represented by a question that provides five response options for grading symptoms. In addition, a question on self-assessment of health status is asked on a visual analog scale from 0 to 100, where 100 is the best imaginable health.	52 weeks
Secondary	PHQ-4: changes in depressivity	The Patient Health Questionnaire-4 (PHQ-4) measures depressiveness and generalized anxiety on two subscales with two items each. For each question, scores from 0 to 3 can be achieved, so that a cumulative score of 12 points can be reached, whereby a higher score indicates a more pronounced symptomatology. The cut-off value for depressivity is defined for the subscales of the PHQ-4 is definied by >= 3 points, the respective attainment of which (independent of the preoperative value) triggers an alarm at each survey time point.	52 weeks
Secondary	PHQ-4: changes in generalised anxiety	The Patient Health Questionnaire-4 (PHQ-4) measures depressiveness and generalized anxiety on two subscales with two items each. For each question, scores from 0 to 3 can be achieved, so that a cumulative score of 12 points can be reached, whereby a higher score indicates a more pronounced symptomatology. The cut-off value for depressivity is defined for the subscales of the PHQ-4 is definied by >= 3 points, the respective attainment of which (independent of the preoperative value) triggers an alarm at each survey time point.	52 weeks
Secondary	PEI: changes in patient enablement	The Patient Enablement Instrument (PEI) measures patient empowerment through six questions; a validated German translation with a modified question sequence and Likert scale is used. Overall, the sum score ranges from 6 to 30 points, with a higher score corresponding to greater patient empowerment.	52 weeks
Secondary	qualitative process evaluation - module 1: feasibility	semi-structured interviews with patients, urologists, psychooncologists, study nurses (N=10-15); data from Module 1 will be evaluated qualitatively using content analysis; criteria are based on the feasibility criteria for evaluating the acceptance and feasibility of the intervention and the study procedures	52 weeks
Secondary	qualitative process evaluation - module 2: impact	sequential semi-structured interviews with patients and relatives from the intervention and control groups in the main study (N=30-40); data from module 2 will be evaluated by contrastive thematic coding; in addition to possible differences between the intervention and control groups, intraindividual changes are also evaluated by contrastive coding of the data material at several time points	52 weeks
Secondary	qualitative process evaluation - module 3: implementation	Semi-structured interviews with urologists, psychooncologists, study nurses in the main study (N=10-15); focus group discussion with study participants; analysis of implementation factors is guided by the Consolidated Framework for Advancing Implementation Science (CFIR); data from module 3 on implementation are evaluated qualitatively by content analysis	52 weeks